Combination Study of SV-BR-1-GM With Retifanlimab
BriaCell Therapeutics Corporation
BriaCell Therapeutics Corporation
University of Nebraska
City of Hope Medical Center
University of Wisconsin, Madison
Dana-Farber Cancer Institute
Sun Yat-sen University
Providence Health & Services
Hoffmann-La Roche
National Cancer Institute (NCI)
Centre Antoine Lacassagne
Tanta University
National Cancer Institute (NCI)
Peking Union Medical College Hospital
Thomas Jefferson University
Beth Israel Deaconess Medical Center
West German Study Group
West German Study Group
Bristol-Myers Squibb
Acepodia Biotech, Inc.
Grand Hôpital de Charleroi
University of Arkansas
University of Arkansas
Prestige Biopharma Limited
Hoffmann-La Roche
UNC Lineberger Comprehensive Cancer Center
Oslo University Hospital
Oslo University Hospital
Spectrum Pharmaceuticals, Inc
Mayo Clinic
AryoGen Pharmed Co.
Hoffmann-La Roche
Sun Yat-sen University
Palleos Healthcare GmbH
NSABP Foundation Inc
G1 Therapeutics, Inc.
European Organisation for Research and Treatment of Cancer - EORTC
Genexine, Inc.
ETOP IBCSG Partners Foundation
Teva Branded Pharmaceutical Products R&D, Inc.
UNICANCER
Capital Medical University
NYU Langone Health
Sheffield Teaching Hospitals NHS Foundation Trust
Indiana University
University of Nebraska
University of Nebraska
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
Dana-Farber Cancer Institute
City of Hope Medical Center